C4 therapeutics launches proposed public offering

Watertown, mass., june 14, 2021 (globe newswire) -- c4 therapeutics, inc. (c4t) (nasdaq: cccc), a clinical-stage biopharmaceutical company pioneering a new class of small-molecule medicines that selectively destroy disease-causing proteins through degradation, today announced that it has launched a proposed public offering of 4,250,000 shares of its common stock.
CCCC Ratings Summary
CCCC Quant Ranking